Treatment of transplant kidneys during machine perfusion

Sarah A Hosgood, Mekhola Hoff, Michael L Nicholson, Sarah A Hosgood, Mekhola Hoff, Michael L Nicholson

Abstract

The increasing use of donation after circulatory death (DCD) and extended criteria donor (ECD) organs has raised awareness of the need to improve the quality of kidneys for transplantation. Treating kidneys during the preservation interval could improve early and long-term graft function and survival. Dynamic modes of preservation including hypothermic machine perfusion (HMP) and normothermic machine perfusion (NMP) may provide the functional platforms to treat these kidneys. Therapies in the field of regenerative medicine including cellular therapies and genetic modification and the application of biological agents targeting ischaemia reperfusion injury (IRI) and acute rejection are a growing area of research. This review reports on the application of cellular and gene manipulating therapies, nanoparticles, anti-inflammatory agents, anti-thrombolytic agents and monoclonal antibodies administered during HMP and NMP in experimental models. The review also reports on the clinical effectiveness of several biological agents administered during HMP. All of the experimental studies provide proof of principle that therapies can be successfully delivered during HMP and NMP. However, few have examined the effects after transplantation. Evidence for clinical application during HMP is sparse and only one study has demonstrated a beneficial effect on graft function. More investigation is needed to develop perfusion strategies and investigate the different experimental approaches.

Keywords: cellular and regenerative therapies; hypothermic machine perfusion; kidney; normothermic machine perfusion.

© 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.

References

    1. Gavriilidis P, Inston NG. Recipient and allograft survival following donation after circulatory death versus donation after brain death for renal transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando) 2020: 100563.
    1. Wan SS, Cantarovich M, Mucsi I, Baran D, Paraskevas S, Tchervenkov J. Early renal function recovery and long-term graft survival in kidney transplantation. Transpl Int 2016; 29: 619.
    1. Kargaard A, Sluijter JPG, Klumperman B. Polymeric siRNA gene delivery - transfection efficiency versus cytotoxicity. J Control Release 2019; 316: 263.
    1. Weissenbacher A, Vrakas G, Nasralla D, Ceresa CDL. The future of organ perfusion and re-conditioning. Transpl Int 2019; 32: 586.
    1. Hosgood SA, van Heurn E, Nicholson ML. Normothermic machine perfusion of the kidney: better conditioning and repair? Transpl Int 2015; 28: 657.
    1. Brasile L, Stubenitsky B. Will cell therapies provide the solution for the shortage of transplantable organs? Curr Opin Organ Transplant 2019; 24: 568.
    1. Sierra-Parraga JM, Eijken M, Hunter J, et al. Mesenchymal Stromal Cells as Anti-Inflammatory and Regenerative Mediators for Donor Kidneys During Normothermic Machine Perfusion. Stem Cells Dev 2017; 26: 1162.
    1. Jochmans I, Akhtar MZ, Nasralla D, et al. Past, Present and Future of Dynamic Kidney and Liver Preservation and Resuscitation. Am J Transplant 2016; 16: 2545.
    1. Hoogduijn MJ, Montserrat N, van der Laan LJW, et al. The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting. Transpl Int 2020; 10: 33.
    1. Horn C, Minor T. Moderne Konzepte zur dynamischen Konservierung von Leber und Nieren im Rahmen einer Transplantation [Modern concepts for the dynamic preservation of the liver and kidneys in the context of transplantation]. Pathologe 2019; 40: 292.
    1. Nicholson ML, Hosgood SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study. Am J Transplant 2013; 13: 1246.
    1. Casiraghi F, Remuzzi G. Mesenchymal stromal cells in kidney transplantation. Curr Opin Nephrol Hypertens 2019; 28: 40.
    1. Pool M, Eertman T, Sierra Parraga J, et al. Infusing Mesenchymal Stromal Cells into Porcine Kidneys during Normothermic Machine Perfusion: Intact MSCs Can Be Traced and Localised to Glomeruli. Int J Mol Sci 2019; 20: 3607.
    1. Sierra-Parraga JM, Munk A, Andersen C, et al. Mesenchymal Stromal Cells Are Retained in the Porcine Renal Cortex Independently of Their Metabolic State After Renal Intra-Arterial Infusion. Stem Cells Dev 2019; 28: 1224.
    1. Pool MBF, Vos J, Eijken M, et al. Treating Ischemically Damaged Porcine Kidneys with Human Bone Marrow- and Adipose Tissue-Derived Mesenchymal Stromal Cells During Ex Vivo Normothermic Machine Perfusion. Stem Cells Dev 2020.
    1. Brasile L, Henry N, Orlando G, Stubenitsky B. Potentiating Renal Regeneration Using Mesenchymal Stem Cells. Transplantation 2019; 103: 307.
    1. Thompson ER, Bates L, Ibrahim IK, et al. Novel delivery of cellular therapy to reduce ischemia reperfusion injury in kidney transplantation. Am J Transplant 2020. .
    1. Grange C, Bellucci L, Bussolati B, Ranghino A. Potential Applications of Extracellular Vesicles in Solid Organ Transplantation. Cells 2020; 9: 369.
    1. Gregorini M, Corradetti V, Pattonieri EF, et al. Perfusion of isolated rat kidney with Mesenchymal Stromal Cells/Extracellular Vesicles prevents ischaemic injury. J Cell Mol Med 2017; 21: 3381.
    1. Tendeiro Rego R, Morris EC, Lowdell MW. T-cell receptor gene-modified cells: past promises, present methodologies and future challenges. Cytotherapy 2019; 21: 341.
    1. Akalin and Bromberg, “Gene Therapy and Solid-Organ Transplantation.” 2002
    1. Li J, Qi G, Tu G, Yang C, Rong R. Gene therapy in kidney transplantation: Evidence of efficacy and future directions. Curr Gene Ther 2017; 17: 434.
    1. Brüggenwirth IMA, Martins PN. RNA interference therapeutics in organ transplantation: The dawn of a new era. Am J Transplant 2020; 20: 931.
    1. Moser MA, Arcand S, Lin HB, et al. Protection of the Transplant Kidney from Preservation Injury by Inhibition of Matrix Metalloproteinases. PLoS One 2016; 11: e0157508.
    1. Zheng X, Zang G, Jiang J, et al. Attenuating Ischemia-Reperfusion Injury in Kidney Transplantation by Perfusing Donor Organs With siRNA Cocktail Solution. Transplantation 2016; 100: 743.
    1. Yang C, Li L, Xue Y, et al. Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA. J Transl Med 2013; 11: 210.
    1. Yang C, Jia Y, Zhao T, et al. Naked caspase 3 small interfering RNA is effective in cold preservation but not in autotransplantation of porcine kidneys. J Surg Res 2013; 181: 342.
    1. Yuzefovych Y, Valdivia E, Rong S, et al. Genetic Engineering of the Kidney to Permanently Silence MHC Transcripts During Ex Vivo Organ Perfusion. Front Immunol 2020; 11: 265.
    1. Cooper DL, Conder CM, Harirforoosh S. Nanoparticles in drug delivery: mechanism of action, formulation and clinical application towards reduction in drug-associated nephrotoxicity. Expert Opin Drug Deliv 2014; 11: 1661.
    1. Tietjen GT, Hosgood SA, DiRito J, et al. Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys. Sci Transl Med 2017; 9: eaam6764.
    1. DiRito JR, Hosgood SA, Reschke M, et al. Lysis of cold-storage-induced microvascular obstructions for ex vivo revitalization of marginal human kidneys. Am J Transplant 2020. .
    1. Situmorang GR, Sheerin NS. Ischaemia reperfusion injury: mechanisms of progression to chronic graft dysfunction. Pediatr Nephrol 2019; 34: 951.
    1. Sedigh A, Larsson R, Brännström J, et al. Modifying the vessel walls in porcine kidneys during machine perfusion. J Surg Res 2014; 191: 455.
    1. Sedigh A, Nordling S, Carlsson F, et al. Perfusion of Porcine Kidneys With Macromolecular Heparin Reduces Early Ischemia Reperfusion Injury. Transplantation 2019; 103: 420.
    1. Hamaoui K, Gowers S, Boutelle M, et al. Organ Pretreatment With Cytotopic Endothelial Localizing Peptides to Ameliorate Microvascular Thrombosis and Perfusion Deficits in Ex Vivo Renal Hemoreperfusion Models. Transplantation 2016; 100: e128.
    1. Brasile L, Glowacki P, Castracane J, Stubenitsky BM. Pretransplant kidney-specific treatment to eliminate the need for systemic immunosuppression. Transplantation 2010; 90: 1294.
    1. Hameed AM, Lu DB, Burns H, et al. Pharmacologic targeting of renal ischemia-reperfusion injury using a normothermic machine perfusion platform. Sci Rep 2020; 10: 6930.
    1. Rogers NM, Zhang ZJ, Wang JJ, Thomson AW, Isenberg JS. CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion. Kidney Int 2016; 90: 334.
    1. Polyak MM, Arrington BO, Stubenbord WT, Kapur S, Kinkhabwala M. Prostaglandin E1 influences pulsatile preservation characteristics and early graft function in expanded criteria donor kidneys. J Surg Res 1999; 85: 17.
    1. Woodside KJ, Goldfarb DA, Rabets JC, et al. Enhancing kidney function with thrombolytic therapy following donation after cardiac death: a multicenter quasi-blinded prospective randomized trial. Clin Transplant 2015; 29: 1173.
    1. Diuwe P, Domagala P, Durlik M, Trzebicki J, Chmura A, Kwiatkowski A. The effect of the use of a TNF-alpha inhibitor in hypothermic machine perfusion on kidney function after transplantation. Contemp Clin Trials 2017; 59: 44.
    1. Chiang CH, Wu CP, Perng WC, Yan HC, Yu CP. Use of anti-(tumour necrosis factor-alpha) antibody or 3-deaza-adenosine as additives to promote protection by University of Wisconsin solution in ischaemia/reperfusion injury. Clin Sci (Lond) 2000; 99: 215.
    1. Tingle SJ, Figueiredo RS, Moir JA, Goodfellow M, Talbot D, Wilson CH. Machine perfusion preservation versus static cold storage for deceased donor kidney transplantation. Cochrane Database Syst Rev. 2019; 3: CD011671.
    1. Darius T, Vergauwen M, Smith TB,, et al. Influence of Different Partial Pressures of Oxygen During Continuous Hypothermic Machine Perfusion in a Pig Kidney Ischemia-reperfusion Autotransplant Model. Transplantation 2020;104: 731.
    1. Minor T, von Horn C, Gallinat A, et al. First-in-man controlled rewarming and normothermic perfusion with cell-free solution of a kidney prior to transplantation. Am J Transplant 2020; 20: 1192.
    1. He X, Chen G, Zhu Z, et al. The First Case of Ischemia-Free Kidney Transplantation in Humans. Front Med (Lausanne) 2019; 6: 276.
    1. Hosgood SA, Saeb-Parsy K, Wilson C, Callaghan C, Collett D, Nicholson ML. Protocol of a randomised controlled, open-label trial of ex vivo normothermic perfusion versus static cold storage in donation after circulatory death renal transplantation. BMJ Open 2017; 7: e012237.
    1. Mavillo F, Ferrari G. Genetic modification of somatic stem cells. The progress, problems and prospects of a new therapeutic technology. EMBO Rep 2008; 9(Suppl 1): S64.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera